← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry+publication
OTOV101N + OTOV101C by OtoVia Therapeutics
Also known as: OTOV101N, OTOV101C, OTOV101N+OTOV101C, OTOV101-IIT-101, AAV gene therapy for DFNB9, NCT05901480
OtoVia Therapeutics
Company
OtoVia Therapeutics
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Interventional/NA
Status
Unknown
Target Gene
OTOF
Route / Mode
Intracochlear injection
Confidence
86%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
China
Population
pediatric, adult, genetic, dfnb9, otof
Trial IDs
1
Mechanism
Dual AAV OTOF gene therapy delivered by intracochlear injection for OTOF mutation-related deafness / DFNB9.
Indications
Notes
Verified as an OtoVia-sponsored OTOF/DFNB9 gene therapy study. Registry status is stale: last known recruiting in 2024 with estimated completion dates in 2024-2025, so current status is kept Unknown rather than overcalling Active.
Evidence & Sources
2 structured sourcesKey Events
Clinical Trials (1)
Data Checks
registry-status-stalecurrent-recruiting-status-needs-update
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2